МЕДИКАМЕНТОЗНОЕ ЛЕЧЕНИЕ ГИПЕРЛИПИДЕМИИ
Аннотация
В обзорной статье освещены современные взгляды на направления и принципы медикаментозного лечения гиперлипидемии, изложены стратегия и тактика проведения терапии.
Литература
Джанашия П.Х., Назаренко В.А., Николенко С.А. Дислипопротеидемии: клиника, диагностика, лечение: Учебное пособие.-Российский государственный медицинский университет. -М.-2000.
Лякишев А.А. Клиническое применение статинов.//Русский медицинский журнал. N 4. -2003. -С. 11.
Майрон Дейвид Дж., Фазио Сергио, Линтон МакРаэ Ф. Современные перспективы применения статинов.//Международный медицинский журнал. -2000. -N6.
Пискун Р.П., Пентюк А.А., Серкова В.К. и соавт. Возможные пути фармакологической коррекции нарушений липидного обмена при атеросклерозе.//Экспериментальная и клиническая фармакология. -1997. -Том 60. -N2.
Прохорович Е.А. Атеросклероз -лечение, профилактика.//Медицинская картотека. -1999. -N4.
Сусеков А.В. Гиперлипидемия -современное состояние проблемы и методы ее медикаментозной коррекции.//Русский медицинский журнал. -2003. -N 5. -С. 11.
Сусеков А.В., Зубарева М.Ю., Рожкова Т.А., Кухарчук В.В. Лескол и коронарный атеросклероз: по результатам трех контролируемых исследований (LCAS, FLARE, LIPS).//Международный медицинский журнал. -2002. -N5(3). -С. 225-233.
Athyros V.G., Papgeorgiou A.A., Mercouris B.R. et al. Treatment with atorvastatin to the national Cholesterol Education Programm Goal versus «Usual» Care inn Secondary Coronary Heart Disease Prevention. The GREek Atorvastatin and Coronary -heart disease evaluation (GREACE) Study.//Current Medical Research and Opinion. -2002. -18(4).-220-228.
Bradford R.H., Shear C.L., Chremos A.N. et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) Study results: Two-year efficacy and safety follow-up.//Am. J. Cardiol. -V.74.-1994.
Brown G., Albers J., Fischer L.B. et al. Regression of coronary artery disease as a result of intensive lipid-lowenng therapy in men with high levels of apoliporotein В.//N. Engl. J.Mod.-1990.-Vol.323.-N19.-P. 1289-1298.
Canner P.L., Berge K.G., Wenger N.K. et al. Fifteen-year mortality in Coronary Drug Project patients: long-term benefitwith niacin.//J. Amer. Coil. Cardiol. -1986.-Vol.8.-P. 1245-1255.
Carlson L.A., Rosenhamer G. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid.//Acta med. scand.-1988.-Vol.223.-P.405-418.
Cromwell W.C., Ziajka P.E. Development of tachyphylaxis among patients taking HMG-CoA reductase inhibitors.//Am J Cardiol.-2000.86.-1123-1127.
Collins R. Heart protection study finds simvastatin reduces vascular risk in a wide range of high-risk patients.//Am. J. Manag. Care.-2002.-Suppl. 6
Downs J.R., Clearfield M., Weis S. et al. Primary prevention of acute coronary events witli lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force. Texas Coronary Atherosclerosis Prevention Study.//J.A.M.A.-1998.-279.1615-1622.
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Рате! III).//J.A.M.A.-2001.-285.-2486-2497.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk patients: a randomized placebo-controlled trial.//Lancet.-2002.-360.-7-22.
Hebert P.R., Gaziano J.M., Chan K.S., Hennekens C.H. Cholesterol lowering with statin drugs, risk of stroke and total mortality: an overview of randomized trials.//J.A.M.A.-1997.-278.-313-321.
Hennekens C.H. Current perspectives on lipid lowering with statins to decrease risk of cardiovascular disease.//Clin. Cardiol.-2001.-24 (suppl. 7).-112-115.
Kane J.P., Malloy M.J., Ports T.A. et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.//J. Amer. med. Assoc.-1990.-Vol. 264.-P.3007-3012.
Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results. Reduction in incidence of coronary heart disease.//J.A.M.A.-1984.-251, 3. -351-364.
Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results. II. The Relationship of reduction in incidence of coronary heart disease to cholesterol lowering.//J.A.M.A.-1984.-251. -365-374.
MAAS Investigators. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS).//Lancet.-V.344.-1994.
MacCarthy E.P. Important Drug Warning, Bayer, Re: Market Withdrawal of Baycol (Cerivastatin) [flyer].//West Haven, Conn.-Bayer Pharmaceutical Division.-August 8.-2001.
Rubins H.B., Robins S.J., Collins D. el al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.//N. Engl. J. Med.-1999.-341.-410418.
Serruys P.W., de Feyter P., Macaya C. et al. Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous Coronary intervention: a randomized controlled trial.//J.A.M.A.-2002.-287(24). -3259-3261.
Shepard J., Cobb S.M., Ford I. et al. For the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.//N.Engl. J.Med.-1995.333.-1301-1307.
Shepherd J., Blauw G.J., Murphy M.B., Bollen E. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial.//Lancet.-2002.-360.-1623-1630.
Stein E.A., Lane M., Laskarzewski P. Effect of statins on triglyceride level.//Am. J. Cardiol.-1998.-81 (Suppl. 4A)/-27B -31B.
The long-term prevention with pravastatin in ischemic disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary Heart disease and a broad range of initial cholesterol levels.//N. Engl. J. Med.-1998.-339.-13491357.
The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S).//Lancet.-V.345.-1995.
